Better Therapeutics, Inc. (NASDAQ:BTTX) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET

Company Participants

Mark Heinen - Chief Financial Officer

Frank Karbe - President and Chief Executive Officer

Mark Berman - Chief Medical Officer

Diane Gómez-Thinnes - Chief Commercial Officer

Conference Call Participants

Thomas Flaten - Lake Street Capital Markets

Rahul Rakhit - LifeSci Capital

Keay Nakae - Chardan

Operator

Good afternoon, and welcome to the Better Therapeutics Third Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.

I would now like to turn the call over to Mark Heinen, Chief Financial Officer. Please begin.

Mark Heinen

Thank you, operator. Good afternoon, everyone. And welcome to the Better Therapeutics conference call to discuss our third quarter 2022 financial results and business update. Our press release was issued this afternoon and can be found in the Investors section of our corporate website bettertx.com.

Joining me on the call today is Frank Karbe, our President and Chief Executive Officer; Dr. Mark Berman, our Chief Medical Officer; and Diane Gomez-Thinnes, our Chief Commercial Officer.

During today's call, we will provide a business and financial overview of the third quarter of 2022 and provide our outlook for the fourth quarter of 2022 and beyond. A Q&A session will follow our prepared remarks.

Before we begin I would like to remind everyone that any statements we make or information presented on this call that are not historical facts or forward-looking statements that are based on our current beliefs plans and expectations that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events and results may differ materially from those expressed or implied by any forward-looking statements due to various risks, uncertainties and other factors including those described in the risk factor section of the most recent SEC filing and any other future filings we make with the SEC. you cautioned not to place any undue reliance on these forward-looking statements. These forward-looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation to publicly update these statements.

With that, I'll pass the call over to Frank Karbe. Frank?